全文获取类型
收费全文 | 41384篇 |
免费 | 3741篇 |
国内免费 | 947篇 |
专业分类
耳鼻咽喉 | 209篇 |
儿科学 | 422篇 |
妇产科学 | 327篇 |
基础医学 | 1352篇 |
口腔科学 | 641篇 |
临床医学 | 6632篇 |
内科学 | 2799篇 |
皮肤病学 | 280篇 |
神经病学 | 1209篇 |
特种医学 | 738篇 |
外国民族医学 | 7篇 |
外科学 | 2070篇 |
综合类 | 7381篇 |
现状与发展 | 2篇 |
一般理论 | 3篇 |
预防医学 | 13848篇 |
眼科学 | 171篇 |
药学 | 4567篇 |
116篇 | |
中国医学 | 2452篇 |
肿瘤学 | 846篇 |
出版年
2024年 | 124篇 |
2023年 | 785篇 |
2022年 | 1160篇 |
2021年 | 1694篇 |
2020年 | 2025篇 |
2019年 | 1453篇 |
2018年 | 1364篇 |
2017年 | 1462篇 |
2016年 | 1555篇 |
2015年 | 1557篇 |
2014年 | 3502篇 |
2013年 | 3549篇 |
2012年 | 3306篇 |
2011年 | 3254篇 |
2010年 | 2553篇 |
2009年 | 2251篇 |
2008年 | 2253篇 |
2007年 | 2027篇 |
2006年 | 1774篇 |
2005年 | 1389篇 |
2004年 | 1202篇 |
2003年 | 1076篇 |
2002年 | 707篇 |
2001年 | 674篇 |
2000年 | 514篇 |
1999年 | 425篇 |
1998年 | 364篇 |
1997年 | 295篇 |
1996年 | 267篇 |
1995年 | 206篇 |
1994年 | 190篇 |
1993年 | 147篇 |
1992年 | 143篇 |
1991年 | 137篇 |
1990年 | 107篇 |
1989年 | 75篇 |
1988年 | 72篇 |
1987年 | 56篇 |
1986年 | 56篇 |
1985年 | 70篇 |
1984年 | 59篇 |
1983年 | 28篇 |
1982年 | 28篇 |
1981年 | 25篇 |
1980年 | 40篇 |
1979年 | 15篇 |
1978年 | 19篇 |
1977年 | 12篇 |
1976年 | 9篇 |
1975年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
《Disability and rehabilitation》2013,35(12):528-535
This paper focuses on two trends in the field of disability and rehabilitation: (a) the desire to conserve resources and yet provide consumers with the highest quality assistive technologies that they find personally appealing and useful; and (b) the involvement of the consumers of rehabilitation services in key decisions regarding the products and services they receive. The Rehabilitation Engineering Research Center on Technology Evaluation and Transfer (Buffalo, NY, USA) has endeavoured to accomplish both by employing a mixed methods approach to consumer-identified needs and preferences regarding several categories of assistive technology. The purpose of this paper is to describe the methods used in sufficient detail for replication by other researchers. 相似文献
992.
993.
《Clinical genitourinary cancer》2022,20(6):594-602
The management of patients with metastatic hormone-sensitive prostate cancer (mHSPC) has been significantly modified by the availability of innovative but expensive treatments, increasing the economic burden of prostate cancer. Here, we aimed to systematically identify and review published economic evaluations (EEs) related to the treatment of mHSPC and assess their quality. A systematic search was performed of the PubMed and Cochrane databases. Three reviewers independently selected EEs by defined inclusion and exclusion criteria. They extracted all data from each EE (general information, study population, data about the EE, interventions and comparators, and outcomes). They also assessed the quality of the selected EEs according to Drummond's checklist. Fourteen EEs published between 2016 and 2021 were eligible for the systematic review. The EEs found ADT + docetaxel to be the most cost-effective of all available treatments as a first-line strategy for mHSPC (abiraterone acetate plus prednisone, enzalutamide, and apalutamide). Five EEs showed that a simple price reduction of abiraterone acetate of 50% to 75% could change the results to render this treatment also cost-effective relative to that with docetaxel. Twelve EEs were of high quality, with a Drummond score ≥ 7. Analysis of the 14 EEs identified by our systematic review, amongst which 78.6% met high quality standards, showed that ADT + docetaxel tends to be the most cost-effective alternative for mHSPC. These results were assessed by sensitivity analysis. The data provided by this systematic review help to provide a better understanding of these treatments and the better use of healthcare resources. 相似文献
994.
995.
5-Bromo-2-deoxyuridine (BrdU) staining is often used to evaluate cortical layer formation during mammalian brain development. This method allows the quantification of newly generated cells and therefore the study of the effects of xenobiotics or genetic factors on proliferation, cell death and migration behavior in a quantitative manner. However, these endpoints are generally assessed by time-consuming manual evaluation. In the present work, we introduce a novel procedure to identify and quantify BrdU+ cells within cortical layers, using the commercially available vHCS-Scan V.6.3.1 software to identify BrdU+ cell coordinates and the novel program ‘BrdeLuxe’ to define cortical layers and quantitatively assign BrdU+ cells to them. This procedure is compared to BrdU+ cell counting with the freeware ‘ImageJ’ in respect to the manual evaluation, all by two different researchers. BrdeLuxe shows high accuracy and precision for the determination of total number of BrdU+ cells compared to the manual counting, while ImageJ does not reach such results. Accuracy and precision are also higher for employing the BrdeLuxe program to evaluate the percentage of BrdU+ cells per brain layer compared to ImageJ. In terms of running time, BrdeLuxe is the fastest method of the three making it more suitable for multiple brain slices analyses. 相似文献
996.
997.
998.
999.
1000.
《Best Practice & Research: Clinical Rheumatology》2016,30(6):981-993
Despite the increased interest in economic evaluations, there are difficulties in applying the results of such studies in practice. Therefore, the “Research Agenda for Health Economic Evaluation” (RAHEE) project was initiated, which aimed to improve the use of health economic evidence in practice for the 10 highest burden conditions in the European Union (including low back pain [LBP] and neck pain [NP]). This was done by undertaking literature mapping and convening an Expert Panel meeting, during which the literature mapping results were discussed and evidence gaps and methodological constraints were identified. The current paper is a part of the RAHEE project and aimed to identify economic evidence gaps and methodological constraints in the LBP and NP literature, in particular.The literature mapping revealed that economic evidence was unavailable for various commonly used LBP and NP treatments (e.g., injections, traction, and discography). Even if economic evidence was available, many treatments were only evaluated in a single study or studies for the same intervention were highly heterogeneous in terms of their patient population, control condition, follow-up duration, setting, and/or economic perspective. Up until now, this has prevented economic evaluation results from being statistically pooled in the LBP and NP literature, and strong conclusions about the cost-effectiveness of LBP and NP treatments can therefore not be made. The Expert Panel identified the need for further high-quality economic evaluations, especially on surgery versus conservative care and competing treatment options for chronic LBP. Handling of uncertainty and reporting quality were considered the most important methodological challenges. 相似文献